title: [Efficiency of sinuforte in combined therapy of acute suppurative rhinosinusitis].
abstract: The objective of this study was to evaluate clinical efficiency and safety of combined therapy including systemic antibiotics, decongestants, and sinuforte in patients with acute suppurative bacterial rhinosinusitis. The patients allocated to two groups comprising 25 subjects each were treated for a total of 8 days. Those in the study group received sinuforte once daily, 10.0 g of amoxilav twice daily, and xylometazole (BID). Control patients were given only amoxilav and xylometazole at the same doses. Dynamics of subjective and objective signs of rhinosinusitis, the mucociliary transport rate, and tolerance of sinuforte were the main variables assessed in this study. The introduction of sinuforte into combined therapy was shown to significantly improve dynamics of subjective and objective signs of rhinosinusitis compared with control. Results of the treatment with sinuforte are described as excellent in 19 patients against 13 in the control group, as good in 4 and 9 patients and satisfactory in 3 and 2 ones respectively. None of the patients needed puncture of maxillary sinuses in the course of the treatment. The mucociliary transport time prior to therapy was estimated at 22.18+/-3.82 and 22.36+/-3.64 in the study and control groups respectively (the difference was insignificant at p>0.05) compared with 14.88+/-3.12 and 16.02+/-3.98 min (p<0.01) on day 8 after the initiation of therapy. The tolerance of sinuforte was estimated at 5.64 based on the 10-score visual-analogous scale. Results of the study confirm that treatment with sinuforte combined with antibiotics (amoxicillin and clavulante) is a safe and efficacious therapeutic modality for the patients with acute bacterial rhinosinusitis.
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Ovchinnikov
authors.forename: G E
authors.initials: GE
authors.lastname: Dzhenzhera
authors.forename: A S
authors.initials: AS
authors.lastname: Lopatin
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D031824:Cyclamen; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy / Q000379:methods*; D028321:Plant Preparations / Q000008:administration & dosage / Q000627:therapeutic use*; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy*; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy*; D013492:Suppuration; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D028321:Plant Preparations